Adma projects 2026 revenue of $530M-$560M and withdraws longer-term guidance amid standard IG dislocation
Source: SeekingAlpha
2026-05-07 04:52:38 ET
More on ADMA Biologics
- ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
- ADMA Biologics: The Short Report Is The Noise, Not The Signal
- ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade)
- ADMA Biologics GAAP EPS of $0.19 in-line, revenue of $114.5M misses by $25.47M
- Summers Value Fund adds TBPH, exits ADMA among Q1 moves
Read the full article on Seeking Alpha
For further details see:
Adma projects 2026 revenue of $530M-$560M and withdraws longer-term guidance amid standard IG dislocation
ADMA Biologics Inc
NASDAQ: ADMA
ADMA Trading
1.2% G/L:
$8.01 Last:
711,250 Volume:
$8.07 Open:
ADMA Latest News
May 21, 2026 05:39:19 pm
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
May 11, 2026 01:47:00 pm
ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation
ADMA Stock Data
$3,926,963,123
229,191,848
0.3%
148
N/A
Biotechnology & Life Sciences
Healthcare
US
Ramsey
